Immunomodulating Agents as Antipruritics - 19/06/18

Résumé |
Chronic pruritus, or itch lasting greater than 6 weeks, is an increasingly common and debilitating medical problem. Recent studies have unveiled previously unrecognized neuroimmune axes whereby inflammatory cytokines act directly on the nervous system to promote itch. Thus, the emergence of newer targeted biologic therapies has generated the possibility of novel treatment strategies for chronic itch disorders. This article reviews the pathophysiology of multiple chronic itch disorders, including atopic dermatitis, chronic idiopathic pruritus, chronic urticaria, and prurigo nodularis. Furthermore, new and emerging immunomodulatory therapies that will likely alter current treatment paradigms are discussed.
Le texte complet de cet article est disponible en PDF.Keywords : Itch, Pruritus, Immunomodulator, Atopic dermatitis, Urticaria, Prurigo nodularis, Chronic idiopathic pruritus
Plan
| Disclosure Statement: B.S. Kim has served on advisory boards for Celgene, Regeneron, and Sanofi. He has worked as a consultant for Incyte and has received support for research from Celgene and LEO Pharma. S. Erickson, Z. Nahmias, and I.S. Rosman have nothing to disclose. |
Vol 36 - N° 3
P. 325-334 - juillet 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
